Scientific and political challenges in North America's first randomized controlled trial of heroin-assisted treatment for severe heroin addiction: Rationale and design of the NAOMI study

Abstract

Background Heroin addiction is a chronic relapsing disease, best treated with opioid-agonist substitution therapy such as methadone maintenance. However, a subset of the most severely affected individuals do not benefit sufficiently from this treatment. The North American Opiate Medication Initiative (NAOMI) is a randomized clinical trial (RCT) to evaluate the hypothesis that pharmaceutical-grade heroin, diacetylmorphine (DAM) is more effective in retaining patients and improving their outcomes than Methadone Maintenance Treatment (MMT) among those with chronic, refractory injection opioid dependence.

Purpose/Methods The study aimed at randomizing 253 participants to two intervention arms: (1) MMT alone or (2) injectable opioids (DAM or hydromorphone) plus adjunctive MMT if deemed appropriate. The planned study duration was 3 years, with a 1-year intake period, 1 year of treatment, and an additional year of follow-up. The NAOMI trial was initiated in March 2005 at two Canadian sites (Vancouver and Montreal). This was the first multicenter RCT in North America to compare the relative efficacy of these different therapeutic strategies. We discuss the rationale behind the NAOMI study design, as well as the scientific and political issues and methodological challenges arising from the conduct of a trial that involves the prescription of a controlled substance to individuals with dependence on that substance.

Limitations Restrictive entry criteria led to the exclusion of many otherwise eligible participants, slowing recruitment into the study. Inability to offer DAM treatment beyond 12 months led to artificial boundary effects in the trial. Conclusions Addiction treatment research navigates between science and politics, and evidence-based medicine is many times confronted by moral beliefs. Political considerations influence study design to a further degree than in RCTs treating less-stigmatized disorders with more-reputable medications.

Get full access to this article

View all access options for this article.

References

Hser YI , Huang D. , Chou CP , Anglin MD Trajectories of heroin addiction: growth mixture modeling results based on a 33-year follow-up study. Eval Rev 2007; 31: 548-63.

Volkow ND , Fowler JS , Wang GJ , Goldstein RZ Role of dopamine, the frontal cortex and memory circuits in drug addiction: insight from imaging studies. Neurobiol Learn Mem 2002; 78: 610-24.

Bailey CP , Connor M. Opioids: cellular mechanisms of tolerance and physical dependence. Curr Opin Pharmacol 2005; 5: 60-8.

Galai N. , Safaeian M. , Vlahov D. , Bolotin A. , Celentano DD Longitudinal patterns of drug injection behavior in the ALIVE Study cohort,1988-2000: description and determinants. Am J Epidemiol 2003; 158: 695-704.

March JC , Oviedo-Joekes E. , Romero M.

Drugs and social exclusion in ten

European cities. Eur Addict Res 2006; 12: 33-41.

Mattick RP , Breen C. , Kimber J. , Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2003; CD002209.

Amato L, Davoli M, A Perucci C, et al. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. J Subst Abuse Treat 2005; 28: 321-9. 8. Van den Brink W, Haasen C. Evidence-based treatment of opioid-dependent patients. Can J Psychiatry 2006; 51: 635-46.

Mattick R. , Kimber J. , Breen C. , Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2008 ; CD002207.

Kraigher D. , Jagsch R. , Gombas W. , et al. Use of slow-release oral morphine for the treatment of opioid dependence. Eur Addict Res 2005; 11: 145-51.

10.

Mitchell TB , White JM , Somogyi AA , Bochner F. Switching between methadone and morphine for maintenance treatment of opioid dependence: impact on pain sensitivity and mood status. Am J Addict 2006; 15: 311-5.

11.

Strain EC , Walsh SL , Bigelow GE Blockade of hydromorphone effects by buprenorphine/naloxone and buprenorphine . Psychopharmacology (Berl) 2002; 159: 161-6.

12.

Krausz M. , Verthein U. , Degkwitz P. , Haasen C. , Raschke P. Maintenance treatment of opiate addicts in Germany with medications containing codeine-results of a follow-up study. Addiction 1998; 93: 1161-7.

13.

Fischer B. , Oviedo-Joekes E. , Blanken P. , et al. Heroin-assisted treatment (HAT) a decade later: a brief update on science and politics. J Urban Health 2007 ; 84: 552-62.

14.

Rehm J. , Gschwend P. , Steffen T. , Gutzwiller F. , Dobler-Mikola A. , Uchtenhangen A. Feasibility, safety, and efficacy of injectable heroin prescription for refractory opioid addicts: a follow-up study. Lancet 2001; 358: 1417-23.

15.

Haasen C. , Verthein U. , Degkwitz P. , et al. Heroin-assisted treatment for opioid dependence: Randomised controlled trial. Br J Psychiatry 2007; 191: 55-62.

16.

Seidenberg A. , Honegger U. Methadon , Heroin und andere Opioide - Medizinisches Manual für die ambulante opioidgestützte Behandlung [Methadone, Heroin and other Opiods - Medical Manual for Outpatient Opioid - Supported Treatment] . Verlag Hans Huber, Bern, 1998.

17.

Farrell M. , Ward J. , Mattick R. , et al. Methadone maintenance treatment in opiate dependence: a review . BMJ 1994; 309: 997-1001.

18.

Schuh KJ , Walsh SL , Stitzer ML Onset, magnitude and duration of opioid blockade produced by buprenorphine and naltrexone in humans. Psychopharmacology ( Berl) 1999; 145: 162-74.

19.

Mayet S. , Farrell M. , Ferri M. , Amato L. , Davoli M. Psychosocial treatment for opiate abuse and dependence. Cochrane Database Syst Rev 2005; CD004330.

20.

Strain EC , Stitzer ML , Liebson IA , Bigelow GE Dose-response effects of methadone in the treatment of opioid dependence. Ann Intern Med 1993; 119: 23-7.

21.

Caplehorn RM , Lumley TS , Irwig L. , Saunders JB Changing attitudes and beliefs of staff working in methadone maintenance programs. Aust N Z J Public Health 1998; 22: 505-8.

22.

Anderson JF , Warren LD Client retention in the British Columbia Methadone Program, 1996-1999. Can J Public Health 2004 ; 95: 104-9.

23.

National Institute on Drug Abuse. Methadone Maintenance Treatment: Translating Research into Policy. NIDA Research Monograph, Washington, DC, 1995.

24.

Strike CJ , Gnam W. , Urbanoski K. , et al. Factors predicting 2-year retention in methadone maintenance treatment for opioid dependence. Addictive Behaviors 2005; 30(5): 1025-8.

25.

Perreault M. , Heroux MC , White ND , et al. Treatment retention and evolution of clientele in a low threshold methadone substitution treatment program in Montreal. Can J Public Health 2007; 98: 33-6.

26.

Farrell M. , Howes S. , Verster AD , Davoli M. Reviewing current practice in drug substitution treatment in the European Union. EMCDDA, Louxembourg, 2000.

27.

Wittchen HU , Apelt SM , Soyka M. , et al. Feasibility and outcome of substitution treatment of heroin-dependent patients in specialized substitution centers and primary care facilities in Germany: a naturalistic study in 2694 patients . Drug Alcohol Depend 2008; 95: 245-57.

28.

Blaney T. , Craig RJ

Methadone maintenance. Does dose determine differences in outcome?

J Subst Abuse Treat 1999; 16: 221-8.

29.

Zule WA , Desmond DP Attitudes toward methadone maintenance: implications for HIV prevention. J Psychoactive Drugs 1998; 30: 89-97.

30.

Fischer B. , Chin AT , Kuo I. , Kirst M. , Vlahov D. Canadian illicit opiate users' views on methadone and other opiate prescription treatment: an exploratory qualitative study. Subst Use Misuse 2002; 37: 495-522.

31.

van den Brink W. , Hendriks VM , Blanken P. , et al. Medical prescription of heroin to treatment resistant heroin addicts: two randomised controlled trials. BMJ 2003; 327: 310.

32.

Hartnoll RL , Mitcheson MC , Battersby A. , et al. Evaluation of heroin maintenance in controlled trial. Arch Gen Psychiatry 1980 ; 37: 877-84.

33.

Guttinger F. , Gschwend P. , Schulte B. , Rehm J. , Uchtenhagen A. Evaluating long-term effects of heroin-assisted treatment: the results of a 6-year follow-up. Eur Addict Res 2003; 9: 73-9.

34.

Perneger TV , Giner F. , del Rio M. , Mino A. Randomised trial of heroin maintenance programme for addicts who fail in conventional drug treatments. BMJ 1998; 317: 13-8.

35.

March JC, Oviedo-Joekes E, Perea-Milla E, Carrasco F. Controlled trial of prescribed heroin in the treatment of opioid addiction. J Subst Abuse Treat 2006; 31: 203-11. 37. Fischer B, Rehm J, Blitz-Miller T. Injection drug use and preventive measures: a comparison of Canadian and western European jurisdictions over time. CMAJ 2000; 162: 1709-13.

36.

Zhang Z. , Friedmann PD , Gerstein DR Does retention matter? Treatment duration and improvement in drug use. Addiction 2003; 98: 673-84.

37.

Kokkevi A. , Hartgers C. EuropASI: European adaptation of a multidimensional assessment instrument for drug and alcohol dependence. European Addiction Research 1995; 1: 208-10.

38.

Darke S. Self-report among injecting drug users: a review. Drug Alcohol Depend 1998; 51: 253-63; discussion 267-8.

39.

Bammer G. , van den Brink W. , Gschwend P. , Hendriks V. , Rehm J. What can the Swiss and Dutch trials tell us about the potential risks associated with heroin prescribing? Drug Alcohol Rev 2003; 22: 363-71.

40.

Ladewig D. , Dursteler-MacFarland KM , Seifritz E. , Hock C. , Stohler R. New aspects in the treatment of heroin dependence with special reference to neurobiological aspects. Eur Psychiatry 2002 ; 17: 163-6.

41.

Stoermer R. , Drewe J. , Dursteler-Mac Farland KM , et al. Safety of injectable opioid maintenance treatment for heroin dependence. Biol Psychiatry 2003; 54: 854-61.

42.

Bland JM , Kerr D. Fifth revision of Declaration of Helsinki. Clause 29 forbids trials from using placebos when effective treatment exists. BMJ 2002; 324: 975.

43.

Kakko J. , Svanborg KD , Kreek MJ , Heilig M. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet 2003; 361: 662-8.

44.

Anonymous National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction. JAMA 1998; 280: 1936-43.

45.

Lepere B. , Gourarier L. , Sanchez M. , et al. Reduction in the number of lethal heroin overdoses in France since 1994. Focus on substitution treatments. Ann Med Interne (Paris) 2001; 152 (Suppl 3): IS5-12.

46.

van Ameijden EJ , Langendam MW , Coutinho RA Dose-effect relationship between overdose mortality and prescribed methadone dosage in low-threshold maintenance programs . Addict Behav 1999; 24: 559-63.

47.

Brugal MT , Domingo-Salvany A. , Puig R. , et al. Evaluating the impact of methadone maintenance programmes on mortality due to overdose and aids in a cohort of heroin users in Spain. Addiction 2005; 100: 981-9.

48.

Fischer B. , Popova S. , Rehm J. , Ivsins A. Drug-related overdose deaths in British Columbia and Ontario, 1992- 2004. Can J Public Health 2006; 97: 384-7.

49.

Healey A. , Knapp M. , Marsden J. , Gossop M. , Stewart D. Criminal outcomes and costs of treatment services for injecting and non-injecting heroin users: evidence from a national prospective cohort survey. J Health Serv Res Policy 2003; 8: 134-41.

50.

Marsch LA The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: a meta-analysis. Addiction 1998; 93: 515-32.

51.

Torrens M. , San L. , Martinez A. , et al. Use of the Nottingham Health Profile for measuring health status of patients in methadone maintenance treatment. Addiction 1997; 92: 707-16.

52.

Fischer B. , Gliksman L. , Rehm J. , Daniel N. , Medved W. Comparing opiate users in methadone treatment with untreated opiate users: results of a follow-up study with a Toronto opiate user cohort. Can J Public Health 1999; 90: 299-303.

53.

Thomson CL , Morley KC , Teesson M. , Sannibale C. , Haber PC Issues with recruitment to randomised controlled trials in the drug and alcohol field: a literature review and Australian case study. Drug Alcohol Rev 2008; 27: 115-22.

54.

van den Brink W. , Hendriks VM , Blanken P. , Huijsman IA , van Ree JM Medical Co-prescription of Heroin: Two Randomized Controlled Trials. Central Committee on the Treatment of Heroin Addicts (CCBH), Netherlands, 2002.

55.

Small DR , Drucker E. Policy makers ignoring science Scientists Ignoring policy: the medical ethical challenges of heroin treatment. Harm Reduct J 2006; 3: 16.

56.

Verthein U. , Bonorden-Kleij K. , Degkwitz P. , et al. Long-term effects of heroin-assisted treatment in Germany. Addiction 2008; 103: 960-6; discussion 967-8.

57.

Oviedo-Joekes E. , March JC , Romero M. , Perea-Milla E. The Andalusian trial on heroin assisted treatment: a 2 years follow-up. Drug Alcohol Rev 2009 ; In press.

58.

Lintzeris N. , Strang J. , Metrebian N. , et al. Methodology for the randomised injecting opioid treatment trial (RIOTT): evaluating injectable methadone and injectable heroin treatment versus optimised oral methadone treatment in the UK. Harm Reduct J 2006; 3: 28.

59.

Oviedo-Joekes E. , Brissette S. , Marsh DC et al. A randomized trial of diacetylmorphine vs. methadone for treatment-refractory opioid addiction. New Engl J Med 2009; In press.

60.

Haasen C. , Vertheim U. , Degkwitz P. The German Model Project for Heroin Assisted Treatment of Opioid Dependent Patients. A Multicentric, Randomized, Controlled Treatment Study. Centre for Interdisciplinary Addiction Research of Hambur University (ZIS), Germany, 2006.